Acuitas Investments’s Adicet Bio ACET Stock Holding History

Acuitas Investments’s Portfolio ACET Stock Details ACET Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-8,549	Closed	-$187K	–	118
2023 Q3	$187K	Buy	+8,549	New	+$302K	0.11%	107

Other funds holding ACET

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Acuitas Investments's ACET Position: Q4 2023 in Review

Acuitas Investments sold out of Adicet Bio (ACET) in Q4 2023, closing a stake of 8,549 shares — an estimated $187K sold.

Acuitas Investments first reported a position in ACET in Q3 2023 and held it in 1 quarter. The position peaked at $187K in Q3 2023. 76 funds tracked by Wall St. Rank hold ACET as of Q4 2023.

Acuitas Investments reported no remaining Adicet Bio position as of Q4 2023 after selling out during the quarter.
Acuitas Investments sold 8,549 Adicet Bio shares in Q4 2023, an estimated $187K.
Acuitas Investments first reported a position in Adicet Bio in Q3 2023 and held it in 1 quarter.
Acuitas Investments's Adicet Bio position peaked at $187K in Q3 2023.
76 funds tracked by Wall St. Rank held Adicet Bio as of Q4 2023.

Based on Acuitas Investments's 13F filing for Q4 2023, filed 2 Feb 2024.